221 related articles for article (PubMed ID: 16509026)
21. Concomitant use of nesiritide and milrinone in decompensated congestive heart failure.
Smull DL; Jorde UP
Am J Health Syst Pharm; 2005 Feb; 62(3):291-5. PubMed ID: 15719588
[No Abstract] [Full Text] [Related]
22. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
23. Rationale, design, and methods for the Transplant-Eligible MAnagement of Congestive Heart Failure (TMAC) trial: a multicenter clinical outcomes trial using nesiritide for TMAC.
Mehra MR; McCluskey T; Barr M; Bourge RC; Jessup ML; Mancini D; Radovancevic B; Rayburn B; Taylor DO; Lilly-Hersley J; Linde P
Am Heart J; 2007 Jun; 153(6):932-40. PubMed ID: 17540193
[TBL] [Abstract][Full Text] [Related]
24. Use of nesiritide before and after publications suggesting drug-related risks in patients with acute decompensated heart failure.
Hauptman PJ; Schnitzler MA; Swindle J; Burroughs TE
JAMA; 2006 Oct; 296(15):1877-84. PubMed ID: 17047218
[TBL] [Abstract][Full Text] [Related]
25. Effect of nesiritide in patients with acute decompensated heart failure.
O'Connor CM; Starling RC; Hernandez AF; Armstrong PW; Dickstein K; Hasselblad V; Heizer GM; Komajda M; Massie BM; McMurray JJ; Nieminen MS; Reist CJ; Rouleau JL; Swedberg K; Adams KF; Anker SD; Atar D; Battler A; Botero R; Bohidar NR; Butler J; Clausell N; Corbalán R; Costanzo MR; Dahlstrom U; Deckelbaum LI; Diaz R; Dunlap ME; Ezekowitz JA; Feldman D; Felker GM; Fonarow GC; Gennevois D; Gottlieb SS; Hill JA; Hollander JE; Howlett JG; Hudson MP; Kociol RD; Krum H; Laucevicius A; Levy WC; Méndez GF; Metra M; Mittal S; Oh BH; Pereira NL; Ponikowski P; Tang WH; Tanomsup S; Teerlink JR; Triposkiadis F; Troughton RW; Voors AA; Whellan DJ; Zannad F; Califf RM
N Engl J Med; 2011 Jul; 365(1):32-43. PubMed ID: 21732835
[TBL] [Abstract][Full Text] [Related]
26. Acutely decompensated heart failure in a county emergency department: a double-blind randomized controlled comparison of nesiritide versus placebo treatment.
Miller AH; Nazeer S; Pepe P; Estes B; Gorman A; Yancy CW
Ann Emerg Med; 2008 May; 51(5):571-8. PubMed ID: 18304693
[TBL] [Abstract][Full Text] [Related]
27. Nesiritide: harmful or harmless?
Dorsch MP; Rodgers JE
Pharmacotherapy; 2006 Oct; 26(10):1465-78. PubMed ID: 16999657
[TBL] [Abstract][Full Text] [Related]
28. [Nesiritide in heart failure: commercial success or therapeutic advance?].
Stampfli T; Perrier A
Rev Med Suisse; 2006 Jan; 2(50):295-8. PubMed ID: 16503047
[TBL] [Abstract][Full Text] [Related]
29. Controversy and conflict in the treatment of acute decompensated heart failure: limited role for nesiritide.
Noviasky JA
Pharmacotherapy; 2007 May; 27(5):626-32. PubMed ID: 17461696
[TBL] [Abstract][Full Text] [Related]
30. Nesiritide, renal function, and associated outcomes during hospitalization for acute decompensated heart failure: results from the Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure (ASCEND-HF).
van Deursen VM; Hernandez AF; Stebbins A; Hasselblad V; Ezekowitz JA; Califf RM; Gottlieb SS; O'Connor CM; Starling RC; Tang WH; McMurray JJ; Dickstein K; Voors AA
Circulation; 2014 Sep; 130(12):958-65. PubMed ID: 25074507
[TBL] [Abstract][Full Text] [Related]
31. Influence of Clinical Trial Site Enrollment on Patient Characteristics, Protocol Completion, and End Points: Insights From the ASCEND-HF Trial (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure).
Greene SJ; Hernandez AF; Sun JL; Metra M; Butler J; Ambrosy AP; Ezekowitz JA; Starling RC; Teerlink JR; Schulte PJ; Voors AA; Armstrong PW; O'Connor CM; Mentz RJ
Circ Heart Fail; 2016 Sep; 9(9):. PubMed ID: 27623769
[TBL] [Abstract][Full Text] [Related]
32. Nesiritide in acute decompensated heart failure: a pooled analysis of randomized controlled trials.
Abraham WT; Trupp RJ; Jarjoura D
Clin Cardiol; 2010 Aug; 33(8):484-9. PubMed ID: 20734445
[TBL] [Abstract][Full Text] [Related]
33. Comparison of the effects of dobutamine and nesiritide (B-type natriuretic peptide) on ventricular ectopy in acutely decompensated ischemic versus nonischemic cardiomyopathy.
Burger AJ; Aronson D; Horton DP; Burger MR
Am J Cardiol; 2003 Jun; 91(11):1370-2. PubMed ID: 12767439
[No Abstract] [Full Text] [Related]
34. Critical review and recommendations for nesiritide use in the emergency department.
Collins SP; Hinckley WR; Storrow AB
J Emerg Med; 2005 Oct; 29(3):317-29. PubMed ID: 16183453
[TBL] [Abstract][Full Text] [Related]
35. Short and long-term mortality with nesiritide.
Arora RR; Venkatesh PK; Molnar J
Am Heart J; 2006 Dec; 152(6):1084-90. PubMed ID: 17161057
[TBL] [Abstract][Full Text] [Related]
36. Safety and efficacy of nesiritide for the treatment of decompensated heart failure.
Emerman CL
Rev Cardiovasc Med; 2002; 3 Suppl 4():S28-34. PubMed ID: 12439428
[TBL] [Abstract][Full Text] [Related]
37. Nesiritide: trials and tribulations.
Arora RR
J Cardiovasc Pharmacol Ther; 2006 Sep; 11(3):165-9. PubMed ID: 17056828
[TBL] [Abstract][Full Text] [Related]
38. Impact of nesiritide on renal function and mortality in patients suffering from heart failure.
Dontas ID; Xanthos T; Dontas I; Lelovas P; Papadimitriou L
Cardiovasc Drugs Ther; 2009 Jun; 23(3):221-33. PubMed ID: 19252976
[TBL] [Abstract][Full Text] [Related]
39. Nesiritide is beneficial or harmful to patients with decompensated acute congestive heart failure.
Ma X; Sun F; Ma J
Int J Cardiol; 2015; 187():387-8. PubMed ID: 25841132
[No Abstract] [Full Text] [Related]
40. Risk of death associated with nesiritide in patients with acutely decompensated heart failure.
Aaronson KD; Sackner-Bernstein J
JAMA; 2006 Sep; 296(12):1465-6. PubMed ID: 17003394
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
